International Journal of Clinical Research

Objective To analyze the clinical comparative differences of different doses of nalbuphine combined with lidocaine in propofol based gastrointestinal endoscopy. Methods A total of 300 patients who underwent painless digestive endoscopy (gastroscopy followed by colonoscopy) at the hospital from March 2024 to January 2025 were selected as the study subjects. According to the principle of drug dosage, they were divided into Group A (intravenous injection of nalbuphine 0.05mg/kg+lidocaine 0.5mg/kg), Group B (intravenous injection of nalbuphine 0.1mg/kg+lidocaine 0.5mg/kg), Group C (intravenous injection of nalbuphine 0.5mg/kg), Group D (intravenous injection of nalbuphine 0.1mg/kg), Group E (intravenous injection of lidocaine 0.5mg/kg), and Group F (intravenous injection of physiological saline), with 50 patients in each group. Compare the severity of injection pain and incidence of adverse reactions caused by propofol in six groups. Results In terms of pain grading caused by propofol injection, Group B was superior to Group A, C, D, E, and F (P<0.05). In terms of the incidence of complications, Group B was lower than Group A, C, D, E, and F (P<0.05). Conclusion The use of 0.1 mg/kg nalbuphine and 0.5 mg/kg lidocaine for propofol based gastrointestinal endoscopy is effective in reducing injection pain caused by propofol and minimizing the occurrence of adverse reactions. It can be further promoted and applied in clinical practice.

Digestive endoscopy examination; Nabufine combined with lidocaine; Propofol causes injection pain; Adverse reaction incidence rate